Evaxion A/S

evaxion.ai

Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Peers: Forward Pharma A/S Damora Therapeutics Inc IO Biotech Inc

Source: SEC 20-F, filed 2026-03-05

Dive deeper

Financial Snapshot

Revenue

TTM

$7.529M

Gross Margin

Last 4 Quarters

N/A

Net Income

TTM

-$9.760M

Current Assets

Last 4 Quarters

N/A

Current Liabilities

Last 4 Quarters

N/A

Current Ratio

Last 4 Quarters

N/A

Total Assets

Last 4 Quarters

N/A

Total Liabilities

Last 4 Quarters

N/A

Book Value

Last 4 Quarters

N/A

Cash

Last 4 Quarters

N/A

P/E

Last 4 Quarters

N/A

Free Cash Flow

TTM

$1.088M

Stock Price

Market Cap: $23.603 Million